Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue biopsy)
Metastatic colorectal carcinoma
Eastern Cooperative Oncology Group of 0, 1 or 2
Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer
Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen is required
Bidimensionally measurable disease
Tumor expressing low to negative levels of epidermal growth factor receptor (EGFr) by immunohistochemistry
At least 2 but no more than 3 prior chemotherapy regimens for metastatic colorectal cancer
Adequate hematologic, renal and hepatic function
You may not be if
Symptomatic brain metastases requiring treatment
Patient with a history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis
Use of systemic chemotherapy or radiotherapy within 30 days before enrollment
Prior anti-EGFr antibody therapy with the exception of the small molecule EGFr tyrosine kinase inhibitors, which are permitted
Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than 1 week) serum half-life within 30 days before enrollment, or prior experimental or approved proteins within 6 weeks before enrollment
Clareo Health | Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
